" class="no-js "lang="en-US"> Astellas Archives - Medtech Alert
Thursday, February 13, 2025

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders

Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]

Astellas Submits New Drug Application for Zolbetuximab in Japan

Astellas Pharma has announced the submission of a New Drug Application (NDA) on June 9, […]

Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) has presented […]

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

Sony Corporation and Astellas Pharma today announced that they have entered into a collaborative research […]

Mogrify and Astellas Announce Collaboration to Conduct Research on in Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more